These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8946658)

  • 1. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
    Stewart S; Voss DW; Northey DL; Horowitz JD
    Ther Drug Monit; 1996 Dec; 18(6):635-9. PubMed ID: 8946658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics.
    Horowitz JD; Sia ST; Macdonald PS; Goble AJ; Louis WJ
    Int J Cardiol; 1986 Nov; 13(2):219-29. PubMed ID: 3793279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes.
    Philpott A; Chandy S; Morris R; Horowitz JD
    Intern Med J; 2004 Jun; 34(6):361-3. PubMed ID: 15228400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide.
    Willoughby SR; Stewart S; Chirkov YY; Kennedy JA; Holmes AS; Horowitz JD
    Eur Heart J; 2002 Dec; 23(24):1946-54. PubMed ID: 12473257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perhexiline.
    Ashrafian H; Horowitz JD; Frenneaux MP
    Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.
    Cole PL; Beamer AD; McGowan N; Cantillon CO; Benfell K; Kelly RA; Hartley LH; Smith TW; Antman EM
    Circulation; 1990 Apr; 81(4):1260-70. PubMed ID: 2180591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
    Jones TE; Morris RG; Horowitz JD
    Br J Clin Pharmacol; 2004 Mar; 57(3):263-9. PubMed ID: 14998422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
    Ling LH; Chik W; Averbuj P; Pati PK; Sverdlov AL; Ngo DT; Morris RG; Sallustio BC; Horowitz JD
    Ther Drug Monit; 2011 Apr; 33(2):251-6. PubMed ID: 21383654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia.
    Sallustio BC; Morris RG
    Ther Drug Monit; 1999 Aug; 21(4):389-94. PubMed ID: 10442691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
    Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
    Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of perhexiline maleate in patients with angina pectoris.
    Burns-Cox CJ; Chandrasekhar KP; Ikram H; Peirce TH; Pilcher J; Quinlan CD; Rees JR
    Br Med J; 1971 Dec; 4(5787):586-8. PubMed ID: 5002115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.
    Killalea SM; Krum H
    Am J Cardiovasc Drugs; 2001; 1(3):193-204. PubMed ID: 14728034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
    Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
    Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perhexiline toxicity related to citalopram use.
    Nyfort-Hansen K
    Med J Aust; 2002 Jun; 176(11):560-1. PubMed ID: 12064991
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
    Sallustio BC; Westley IS; Morris RG
    Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perhexiline maleate in the treatment of angina pectoris in patients awaiting coronary artery bypass surgery.
    Armstrong ML
    Curr Med Res Opin; 1976-1977; 4(10):725-31. PubMed ID: 800973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perhexiline maleate in the treatment of angina pectoris. Five years of personal clinical experience.
    Wallace DC
    Med J Aust; 1978 Nov; 2(10):466, 493-5. PubMed ID: 33322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perhexiline maleate in the treatment of severe angina pectoris.
    Horowitz JD; Mashford ML
    Med J Aust; 1979 Jun; 1(11):485-8. PubMed ID: 470697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perhexiline--stable plasma concentrations with formulation change.
    Siebert WJ; Gabb GM; Wing LM
    Aust N Z J Med; 1996 Oct; 26(5):707-8. PubMed ID: 8958370
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
    Cohen M; Xiong J; Parry G; Adams PC; Chamberlain D; Wieczorek I; Fox KA; McBride R; Chesebro JH; Fuster V
    J Am Coll Cardiol; 1993 Nov; 22(5):1338-43. PubMed ID: 7901254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.